NCT05994547 is a Phase 4 clinical trial of Byfavo in Bronchoscopy, sponsored by Chungbuk National University Hospital.

Who is sponsoring NCT05994547?

NCT05994547 is sponsored by Chungbuk National University Hospital.

What drugs are being tested in NCT05994547?

Interventions in NCT05994547: Byfavo, Midazolam.

What condition does NCT05994547 study?

NCT05994547 studies Bronchoscopy, Remimazolam.

Is NCT05994547 still recruiting?

NCT05994547 is currently completed. Last updated 16 August 2023.

Last reviewed 2023-08-16 · How we verify

NCT05994547

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy and Safety of Remimazolam Compared With Midazolam During Bronchoscopy:Randomised Controlled Trial

Completed Phase 4 Last updated 16 August 2023

What this trial tests

Phase 4 trial testing Byfavo in Bronchoscopy in 100 participants. Completed in 15 June 2023.

Timeline

14 April 2022

Primary endpoint
15 June 2023

15 June 2023

Quick facts

Lead sponsor	Chungbuk National University Hospital
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	100
Start date	14 April 2022
Primary completion	15 June 2023
Estimated completion	15 June 2023
Sites	1 location across South Korea

Drugs / interventions tested

Byfavo — full drug profile →
Midazolam (midazolam) — full drug profile →

Conditions studied

Bronchoscopy — all drugs for Bronchoscopy →
Remimazolam — all drugs for Remimazolam →

Sponsor

Chungbuk National University Hospital

Who can join

18 and older, any sex, with Bronchoscopy or Remimazolam. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Objectives: Although remimazolam is an ultra-short-acting benzodiazepine with a shorter elimination half-life and faster recovery time than midazolam, studies evaluating its safety and efficacy during bronchoscopy are limited. This study compared the safety and efficacy of remimazolam with that of midazolam for bronchoscopy. Design: A single-center, prospective randomized parallel-group study Setting: Chungbuk National University Hospital, April 2022-June 2023. Participants: One hundred patients were enrolled; 51 were randomly assigned to the midazolam group and 49 to the remimazolam group. Respiratory nurse specialists performed the randomization. Interventions: Oral and laryngeal anesthesia was induced using a 4% lidocaine nebulizer prior to sedation. The vocal cords and lower airway tract were anesthetized. Patients aged \<60 years or weighing \>50 kg received 3 mg intravenous midazolam or 5 mg remimazolam. Patients aged ≥60 years or weighing \<50 kg received 2 mg intravenous midazolam or 3 mg remimazolam. Bronchoscopy was performed under adequate sedation (MOAA/S≤3) Main outcome measures: The primary outcome was the time from the end of the procedure to full alertness. Secondary outcomes were procedural time parameters, satisfaction profiles, and adverse effects.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Safety and efficacy of remimazolam compared with midazolam during bronchoscopy: a single-center, randomized controlled study.
Kim SH, Cho JY, Kim M, Chung JM, et al · · 2023 · cited 27× · PMID 37993525 · DOI 10.1038/s41598-023-47271-w

Verify or expand the search:

Other trials of Byfavo

Trials testing the same drug.

NCT06275594 — Trial Evaluating the Efficacy of Remimazolam in Endobronchial Ultrasound Guided Transbronchial Needle Aspiration · Phase 2 · unknown

Other recruiting trials for Bronchoscopy

Currently open trials in the same condition.

NCT07368829 — AI-Driven Autonomous Registration in Robotic Bronchoscopy · NA · recruiting
NCT07517926 — Chewing Gum and Cold Gargle on Post-Bronchoscopy Symptoms · NA · recruiting
NCT07006311 — Robotic-assisted Bronchoscopy Under Moderate Sedation With Propofol · NA · recruiting
NCT07057648 — Shape-Sensing Robotic-Assisted Bronchoscopy for Diagnosis of Peripheral Pulmonary Nodules in Korea · recruiting
NCT06953414 — Classification and Prediction of Difficult Awake Tracheal Intubation With Flexible Bronchoscopes · recruiting

Other Chungbuk National University Hospital trials

Trials by the same sponsor.

NCT07037303 — Comparing Active Cycle of Breathing Techniques (ACBT) and Aerobika in Treating Bronchiectasis in Korea · NA · not yet recruiting
NCT04552574 — Randomized Clinical Trial of HMR(Home Meal Replacement)-Type Omega-3-balanced-diet · NA · unknown
NCT04893148 — Efficacy and Safety of iGlarLixi Versus Insulin Glargine Plus Dulaglutide in Patients With Type 2 Diabetes · Phase 4 · unknown
NCT04647838 — Tepotinib in Solid Tumors Harboring MET Alterations · Phase 2 · unknown
NCT03473262 — Empagliflozin-based Quadruple Combination vs Insulin Glarine-based Combination Therapy in Patients With Type 2 Diabetes · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05994547 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chungbuk National University Hospital
Last refreshed: 16 August 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05994547.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing